News of Note—Dynavax, Emergent BioSolutions and more

newspapers
In this week's News of Note, Dynavax steadily grew sales of its novel hepatitis B vaccine, Heplisav-B. (Pixabay)

Here is some other vaccine news of note for the week:

> Dynavax’s hepatitis B vaccine Heplisav-B sold $1.3 million in the second quarter, up from $0.2 million in the first quarter. Release

> Emergent BioSolutions posted second-quarter revenue of $220 million, an increase of 118% year over year, thanks to sales of anthrax vaccine BioThrax and smallpox vaccine ACAM2000. Release

INDUSTRY RESEARCH

Veeva 2019 Unified Clinical Operations Survey

Share your thoughts in this quick survey. The first 50 qualified respondents will receive a $5 Amazon gift card, and, in appreciation for your time, all qualified survey respondents will be entered in a drawing to win a $50 Amazon gift card.

> Changchun Changsheng Life Sciences, embroiled in China’s latest vaccine scandal, was found to have forged production data for more than four years. Xinhua article

> The International AIDS Vaccine Initiative reached a nonexclusive license agreement with the Public Health Agency of Canada to obtain vesicular stomatitis virus vector technology for a Lassa fever vaccine currently under funding from the Coalition for Epidemic Preparedness Innovations. Release